The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Could MRD become a surrogate endpoint for drug approval in AML?
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on the potential role of measurable residual disease (MRD) as a surrogate endpoint for drug approval in acute myeloid leukemia (AML), emphasizing the need to measure MRD in patients with FLT3-ITD-positive and NPM1-mutated disease. Dr Perl highlights the importance of using sensitive MRD assays to monitor relapse-free survival and guide therapy decisions. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
